Blog

Medical cannabis programs represent an extraordinary achievement in healthcare innovation. For decades under federal prohibition, patients, advocates, scientists, businesses, and state regulators developed systems to deliver complex botanical medicines to millions of patients outside the traditional pharmaceutical framework. States built medical cannabis regulatory systems without coordinated federal product safety infrastructure, national manufacturing standards, or the research and oversight systems available to conventional medicines.

Medical cannabis programs did more than establish legal access. They pioneered approaches to cultivation, manufacturing, laboratory testing, product labeling, and distribution that made regulated access to whole-plant cannabis possible. These innovations not only improve cannabis safety but also offer a pathway for integrating whole-plant cannabis into mainstream healthcare and advancing the future of botanical medicine.

From Product Transparency to Informed Patient Care

One of the greatest challenges in integrating cannabis into healthcare is connecting what we know about the plant, what researchers are discovering, what manufacturers are producing, what healthcare professionals understand, and what patients are experiencing. Cannabis products contain complex combinations of cannabinoids, terpenes, and other constituents, with variations in potency, formulation, and methods of administration. Understanding these differences is essential to advancing clinical research, improving treatment decisions, developing better products, and establishing meaningful safety standards.

Patients should have the same confidence in their medical cannabis products as they do in other medicines: that the product contains what its label says, that its potency and quality are consistent, that it has been tested for contaminants, and that reliable safety information is available. This confidence cannot come from labeling requirements alone. Rigorous testing, transparent manufacturing practices, reliable product identification, and systems that can track products and respond quickly when safety concerns arise must support it.

If we want whole-plant medical cannabis fully integrated into our healthcare systems, patients and healthcare professionals must be able to trust the quality, consistency, and information associated with the medicines they use. Reliable, accessible product information can support informed decisions about dosing, potential drug interactions, adverse effects, treatment outcomes, and individual patient needs. Just as importantly, it can give healthcare professionals greater confidence in discussing cannabis as a treatment option and incorporating it into patient care.

It can also help researchers link product characteristics to patient experiences and clinical outcomes, help manufacturers develop safer, more consistent formulations, and help regulators identify and respond to emerging safety concerns. Connecting these sources of information is essential to building the clinical knowledge, professional confidence, and regulatory infrastructure needed to bring whole-plant cannabis medicine into mainstream healthcare.

Creating the Infrastructure for the Next Generation of Cannabis Medicine

The next chapter of medical cannabis will require more than stronger labeling requirements or additional laboratory reports. It will require systems that connect product development, laboratory testing, scientific research, professional education, clinical practice, and patient experiences. This presents an opportunity to advance a new approach to transparent pharmacology, one that recognizes the complexity of botanical medicines and makes information about their composition, quality, and effects accessible and useful throughout the healthcare system.

The 2026 Full Disclosure Award nominees are helping build that foundation. Their innovations demonstrate how transparency can become more than a regulatory obligation. By making product information accurate, accessible, verifiable, and actionable, they are developing tools that can improve patient safety, support informed medical decisions, strengthen research, and help make reliable medical cannabis access more scalable.

Full disclosure is not simply about providing more data. It is about turning information into knowledge that patients, healthcare professionals, researchers, manufacturers, and regulators can use. The Full Disclosure Award recognizes products, laboratories, platforms, labeling systems, traceability tools, and transparency initiatives that make cannabis testing results, ingredients, potency, warnings, batch information, recalls, sourcing, and product instructions easier to understand and verify.

The 2026 nominees- SafeTiva Labs, ClearSight Labs, MCR Labs, and Kanha Technology Solutions are advancing innovations that connect cannabis product safety with patient care, scientific research, professional education, and regulatory oversight. Their work builds on the systems developed under prohibition, helping lay the foundation for more transparent, reliable, and scalable medical cannabis access and the integration of whole-plant cannabis into mainstream healthcare.

Learn more about the Full Disclosure Award!

MEET THE FULL DISCLOSURE AWARD NOMINEES

SafeTiva Labs

SafeTiva Labs is an independent Massachusetts cannabis testing laboratory built around accurate testing, scientific integrity, and transparent results. The laboratory tests cannabis for potency, pesticides, residual solvents, microbial contaminants, heavy metals, mycotoxins, terpenes, and other safety measures, while also helping cultivators and manufacturers understand their analytical results and address problems they identify.

SafeTiva has also called attention to broader testing practices that can undermine confidence in cannabis labels, including laboratory shopping and commercial pressure around potency and failure rates. Its work reinforces a central part of full disclosure: patients need to trust the numbers they are given.

ClearSight Labs

ClearSight Labs opened as the first cannabis testing laboratory in the nation’s capital, giving Washington, DC’s medical cannabis program an independent laboratory capable of analyzing products before they reach patients. Its testing addresses potency, terpenes, residual solvents, microbial contaminants, pesticides, mycotoxins, and other safety measures.

ClearSight also works to make laboratory information understandable to users, including through patient-facing tools that explain Certificates of Analysis. Testing creates information, but transparency lets patients understand and use it.

MCR Labs

MCR Labs has expanded transparency beyond individual test reports by examining how cannabis testing systems perform across multiple states. Its work uses large collections of public compliance-testing data to identify patterns associated with issues such as potency inflation, laboratory shopping, unusually low contaminant failure rates, and results clustered near regulatory limits.

By making testing data and analysis available to regulators, researchers, journalists, and the public, MCR Labs helps make the testing system's performance open to scrutiny. Its work gives stakeholders additional tools to identify warning signs, ask better questions, and determine where further investigation or independent testing may be needed.

Kanha Technology Solutions

Kanha Technology Solutions develops digital infrastructure for licensing, compliance, traceability, patient access, and regulatory oversight. Its systems give governments and operators greater visibility across the regulated cannabis supply chain, including where products came from and how they moved through regulated systems.

Traceability becomes particularly important when a safety problem is discovered. Digital systems that connect products, operators, transactions, and regulatory information help identify affected products faster while giving regulators clearer information about what happened and where corrective action is needed.

From State Innovation to the Future of Medicine

Medical cannabis programs proved that regulated access to whole-plant botanical medicine was possible, even under federal prohibition. The next challenge is integrating the knowledge, products, and systems developed through those programs into a more coordinated healthcare framework.

The 2026 Full Disclosure Award nominees are helping make that future possible. Their work represents more than improvements in testing or labeling. It helps establish the connections between product quality, scientific research, clinical decision-making, and patient experiences that are essential to understanding and advancing whole-plant cannabis medicine. The future of medical cannabis depends not only on making safe products available, but on making the information behind those products reliable, understandable, and useful throughout the healthcare system. By advancing transparency and accountability, these nominees are helping transform innovations born under prohibition into the foundation for a new generation of patient-centered botanical medicine.

Learn more about the nominees & cast your vote for the 2026 Full Disclosure Award through October 25.